Chowell, Diego
Krishna, Chirag
Pierini, Federica
Makarov, Vladimir
Rizvi, Naiyer A.
Kuo, Fengshen http://orcid.org/0000-0003-1797-2896
Morris, Luc G. T. http://orcid.org/0000-0002-4417-2280
Riaz, Nadeem
Lenz, Tobias L. http://orcid.org/0000-0002-7203-0044
Chan, Timothy A. http://orcid.org/0000-0002-9265-0283
Article History
Received: 9 April 2019
Accepted: 3 October 2019
First Online: 7 November 2019
Competing interests
: T.A.C. is a co-founder of Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H and Eisai. T.A.C. has served as an advisor for Bristol-Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca and An2H. N.A.R. is a consultant/advisory board member for AstraZeneca, BMS, Roche, Merck, Novartis, Lilly and Pfizer. T.A.C. and N.A.R are cofounders of Gritstone Oncology. T.A.C., N.A.R, L.G.T.M. and D.C. hold ownership of intellectual property on using TMB to predict immunotherapy response, with pending patent, which has been licensed to PGDx.